MG
LLY icon

Michael Gelband’s Eli Lilly LLY Stock Holding History

Michael Gelband’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Sell
14,472
-11,227
-44% -$11.5M 0.11% 159
2026
Q1 		$23.6M Buy
+25,699
New +$26.1M 0.19% 76
2025
Q3 		– Sell
-23,579
Closed -$18.4M – 1803
2025
Q2 		$18.4M Buy
+23,579
New +$18.3M 0.16% 126
2024
Q4 		– Sell
-14,285
Closed -$12.7M – 1805
2024
Q3 		$12.7M Sell
14,285
-13,739
-49% -$12.4M 0.08% 195
2024
Q2 		$25.4M Buy
+28,024
New +$22.4M 0.17% 97
2024
Q1 		– Sell
-13,478
Closed -$9.59M – 1755
2023
Q4 		$7.86M Sell
13,478
-29,910
-69% -$17.5M 0.05% 247
2023
Q3 		$23.3M Buy
+43,388
New +$22.4M 0.22% 81
2022
Q4 		– Sell
-49,501
Closed -$16M – 1908
2022
Q3 		$16M Sell
49,501
-37,452
-43% -$11.9M 0.21% 101
2022
Q2 		$28.2M Buy
+86,953
New +$26.1M 0.35% 36
2022
Q1 		– Sell
-27,582
Closed -$7.62M – 2459
2021
Q4 		$7.62M Buy
27,582
+16,694
+153% +$4.23M 0.08% 289
2021
Q3 		$2.52M Sell
10,888
-9,511
-47% -$2.35M 0.03% 635
2021
Q2 		$4.68M Sell
20,399
-14,736
-42% -$2.96M 0.05% 382
2021
Q1 		$6.56M Buy
+35,135
New +$6.87M 0.1% 203
2020
Q4 		– Sell
-146,672
Closed -$21.7M – 2192
2020
Q3 		$21.7M Buy
146,672
+114,932
+362% +$17.8M 0.43% 25
2020
Q2 		$5.21M Buy
+31,740
New +$4.87M 0.14% 154
2019
Q3 		– Sell
-3,741
Closed -$414K – 1498
2019
Q2 		$414K Buy
+3,741
New +$441K 0.02% 553
2019
Q1 		– Sell
-2,106
Closed -$244K – 723
2018
Q4 		$244K Buy
+2,106
New +$235K 0.02% 227

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's LLY Position: Q2 2026 in Review

Michael Gelband reduced its Eli Lilly (LLY) stake by 44% in Q2 2026, selling an estimated $11.5M and leaving 14,472 shares worth $17.4M. The position accounts for 0.11% of the portfolio, ranked #159.

Michael Gelband first reported a position in LLY in Q4 2018 and has held it in 17 quarters since. The position peaked at $28.2M in Q2 2022. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Michael Gelband held 14,472 shares of Eli Lilly worth $17.4M as of Q2 2026.
  • Michael Gelband sold 11,227 Eli Lilly shares in Q2 2026, an estimated $11.5M.
  • Eli Lilly made up 0.11% of Michael Gelband's portfolio in Q2 2026, its #159 holding.
  • Michael Gelband first reported a position in Eli Lilly in Q4 2018 and has held it in 17 quarters since.
  • Michael Gelband's Eli Lilly position peaked at $28.2M in Q2 2022.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.